Compare THEO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THEO | CRBP |
|---|---|---|
| Founded | 2025 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.7M | 190.3M |
| IPO Year | 2025 | 2014 |
| Metric | THEO | CRBP |
|---|---|---|
| Price | $9.95 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $33.22 |
| AVG Volume (30 Days) | 93.8K | ★ 1.1M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $9.82 | $2.81 |
| 52 Week High | $10.03 | $12.88 |
| Indicator | THEO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 68.44 | 34.65 |
| Support Level | $9.87 | $2.81 |
| Resistance Level | $10.00 | $8.13 |
| Average True Range (ATR) | 0.02 | 0.43 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 40.00 | 39.54 |
BOA Acquisition Corp II is a blank check company.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.